Clinical Trials Browser

Phase 1/2 × Select Advanced Solid Tumors × atezolizumab × Clear all

NCT03973333 2024-10-18

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Phase 1/2 Withdrawn

Other solid neoplasm

Select Advanced Solid Tumors